<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04742803</url>
  </required_header>
  <id_info>
    <org_study_id>1116</org_study_id>
    <nct_id>NCT04742803</nct_id>
  </id_info>
  <brief_title>Epistamp Needling Treatment For Skin Rejuvenation</brief_title>
  <acronym>ESAA</acronym>
  <official_title>Face Study of the Effects of Needling Using the Epistamp for the Improvement of Fine Lines, Deep Wrinkles, and Collagen Production.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universal Skincare Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lavish Beauty</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universal Skincare Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study will expand knowledge and application needling using the Epistamp device for&#xD;
      the improvement of a new vitalized epidermal layer with new vibrant active cells, supported&#xD;
      by more robust collagen and elastin fine lines, deep wrinkles, and collagen production.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot study will expand the knowledge and application needling using the Epistamp device&#xD;
      and its benefits for improving the appearance of fine lines, deep wrinkles, and collagen&#xD;
      production. The pilot aims to objectively measure skin quality using the Derma Scan,&#xD;
      photographs and provide objective data showing improvement by way of the Universal Skincare&#xD;
      Institute Blood Flow Scale.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 20, 2021</start_date>
  <completion_date type="Anticipated">September 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Skin improvement assessed by Derma Scan</measure>
    <time_frame>6 months</time_frame>
    <description>The Derma Scan System utilizes two special lighting systems (RGB +UV) and smart skin analyzer software that allows two images (before and after care) to be compared side by side, which can be used to detect the changes in skin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Universal Skincare Institute Blood Flow Scale (USIBFS)</measure>
    <time_frame>6 months</time_frame>
    <description>Improvement in fine lines, deep wrinkles, and collagen production by simulating cellular reproduction by triggering skins own inflammation response. The scale will be completed at every office visit over the 6 month study. Temperature will be taken of 4 areas on the face before and after each treatment. 1 = 1% to 25%, 2 = 26 to 50%, 3 = 51 to 75%, 4 = &gt;76% improvement in blood flow to the area).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Global Aesthetic Improvement Scale (GAIS)</measure>
    <time_frame>6 months</time_frame>
    <description>The Global Aesthetic Improvement Scale (GAIS) is a 5-point scale rating global aesthetic improvement in appearance, compared to pretreatment, as judged by the investigator 5 point scale ranging from 1 to 5 with 5 = The appearance has worsen compared with the original condition and 1 = Excellent corrective results investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Photographs</measure>
    <time_frame>6 months</time_frame>
    <description>Digital imaging device using a grid background with controlled lighting and setting to grade acne scar improvement on a quartile grading scale(1 = 1% to 25%, 2 = 26 to 50%, 3 = 51 to 75%, 4 = &gt;76% improvement).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the impact on the quality of life (DLQI)</measure>
    <time_frame>6 months</time_frame>
    <description>The Dermatology Life Quality Index questionnaire (DLQI) is 10 questions were asked to the patients and score is 0-3 for each question. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wrinkle Severity Rating Scale (WSRS)</measure>
    <time_frame>6 months</time_frame>
    <description>The Wrinkle Severity Rating Scale assesses the presence and severity of wrinkles at rest in a rating scale from 0 to 4, where 0 means no visible wrinkles, 1 means minimal wrinkles, 2 means shallow wrinkles, 3 means moderately deep wrinkles and 4 means very deep wrinkles.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Wrinkle</condition>
  <condition>Elastic Skin</condition>
  <condition>Collagen Degeneration</condition>
  <arm_group>
    <arm_group_label>Epistamp Needling Treatment Without RF</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Non-Randomized treatment for patients who seek improvement for elastin, fine lines, deep wrinkles, and collagen production using Epistamp needling without RF (Radio Frequency)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epistamp Needling Treatment With RF</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Non-Randomized treatment for patients who seek improvement for elastin, fine lines, deep wrinkles, and collagen production using Epistamp needling with RF (Radio Frequency)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Epistamp</intervention_name>
    <description>The patient's entire face will be treated with the Epistamp needling device.&#xD;
The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm</description>
    <arm_group_label>Epistamp Needling Treatment With RF</arm_group_label>
    <arm_group_label>Epistamp Needling Treatment Without RF</arm_group_label>
    <other_name>Needling</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Derma Scan showing aging including skin texture, wrinkles, brown spots, and pores.&#xD;
&#xD;
          -  Patients willing to sign informed consent.&#xD;
&#xD;
          -  Patients willing to be photographed and video documented&#xD;
&#xD;
          -  Patients willing to consent to 3 months of treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of eczema in the treatment area; psoriasis and any other chronic skin&#xD;
             conditions&#xD;
&#xD;
          -  History of actinic (solar) keratosis in the treatment area;&#xD;
&#xD;
          -  History of hemophilia&#xD;
&#xD;
          -  History of diabetes&#xD;
&#xD;
          -  The presence of raised moles, warts on the targeted area.&#xD;
&#xD;
          -  Collagen vascular diseases or cardiac abnormalities&#xD;
&#xD;
          -  Blood clotting problems&#xD;
&#xD;
          -  Active bacterial or fungal infection&#xD;
&#xD;
          -  Facial melanosis&#xD;
&#xD;
          -  Malignant tumors&#xD;
&#xD;
          -  Immunosuppression&#xD;
&#xD;
          -  Use of blood thinners or prednisone&#xD;
&#xD;
          -  Corticosteroids within two weeks of the procedure&#xD;
&#xD;
          -  Chronic liver disease&#xD;
&#xD;
          -  Porphyria or other skin diseases.&#xD;
&#xD;
          -  Patient not willing to sign informed consent.&#xD;
&#xD;
          -  TCA peels in the last 5 weeks&#xD;
&#xD;
          -  Subject currently has moderate to severe acne on the face.&#xD;
&#xD;
          -  Microneedling within the last 6 months&#xD;
&#xD;
          -  Subject has an active infection.&#xD;
&#xD;
          -  Subject has a history of a bleeding disorder&#xD;
&#xD;
          -  Subject has a history of keloidal tendency&#xD;
&#xD;
          -  Subject has received ablative or non-ablative laser treatments in the previous 6&#xD;
             months.&#xD;
&#xD;
          -  Subject has taken Accutane within the previous 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurice Wright, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University/ Harlem Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leslie L Nesbitt</last_name>
    <role>Study Chair</role>
    <affiliation>Universal Skincare</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven Wong, MD</last_name>
    <phone>646-838-4154</phone>
    <phone_ext>3</phone_ext>
    <email>leslie@universalskincareinstitute.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michelle Jenkins, TECH</last_name>
    <phone>646-838-4154</phone>
    <phone_ext>3</phone_ext>
    <email>michellej@lavish-nyc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lavish</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Leslie Nesbitt, Tech</last_name>
      <phone>646-838-4154</phone>
      <email>trials@universalskincareinstitute.com</email>
    </contact>
    <contact_backup>
      <last_name>Steven Wong, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://universalskincareinstitute.com/</url>
    <description>Derma Scan</description>
  </link>
  <reference>
    <citation>Goodman GJ, Baron JA. Postacne scarring: a qualitative global scarring grading system. Dermatol Surg. 2006 Dec;32(12):1458-66.</citation>
    <PMID>17199653</PMID>
  </reference>
  <reference>
    <citation>Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May;19(3):210-6.</citation>
    <PMID>8033378</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 1, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>microneedling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ehlers-Danlos Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Once the overall trial is completed and sensitive detailed information is legally advised to published.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

